Prise en charge initiale actuelle des ­carcinomes ovariens séreux de haut grade avancés [Current management of advanced high grade serous ovarian carcinomas]

Détails

Ressource 1Demande d'une copie Sous embargo jusqu'au 16/04/2026.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_33A75F2F4F0F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Prise en charge initiale actuelle des ­carcinomes ovariens séreux de haut grade avancés [Current management of advanced high grade serous ovarian carcinomas]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Durand Y., Nicod Lalonde M., Hastir D., Astarita A., Mathevet P.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
16/10/2024
Peer-reviewed
Oui
Volume
20
Numéro
891
Pages
1848-1854
Langue
français
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Résumé
Ovarian cancers are gynecological cancers with a poor prognosis. Most ovarian cancers are high-grade serous carcinomas. It is now accepted that they are very often tubal in origin. Their management has undergone major advances in recent years. Their clinical manifestations are not very specific, and no screening test has yet -proved its worth, which explains why they are often diagnosed late. The diagnostic phase is essentially based on ultrasound and abdomino-pelvic CT scans, for reasons of ease of access. Other -examination modalities, such as MRI and above all PET-Ct, are playing an increasingly important role in the initial management of extension or thera-peutic follow-up. Even with notable advances in diagnosis and treatment, the overall prognosis remains poor.
Mots-clé
Humans, Female, Ovarian Neoplasms/therapy, Ovarian Neoplasms/diagnosis, Ovarian Neoplasms/pathology, Cystadenocarcinoma, Serous/therapy, Cystadenocarcinoma, Serous/diagnosis, Cystadenocarcinoma, Serous/pathology, Prognosis, Neoplasm Grading
Pubmed
Création de la notice
28/10/2024 14:09
Dernière modification de la notice
29/10/2024 7:25
Données d'usage